Efficacy and safety of T-DXd versus Other HER2-targeted therapies in second-line and later settings for HER2-positive metastatic breast cancer: A Bayesian network meta-analysis
Yu Xiao, Jing Fu, Juan Li, Gang Hu · 2026
Read Efficacy and safety of T-DXd versus Other HER2-targeted therapies in second-line and later settings for HER2-positive metastatic breast cancer: A Bayesian network meta-analysis by Yu Xiao, Jing Fu, Juan Li, Gang Hu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0358540.txt.
Description
Xiao and three co-authors published a 2026 PLOS ONE study comparing drugs for advanced breast cancer. All the cancers were HER2-positive and had spread. The team weighed one drug, T-DXd, against other HER2-targeted options used after first treatment failed. They used a Bayesian network method that pools many trials at once. Rankings like this help doctors choose when no single trial compares every option.
Catalog record
| CREATOR | Yu Xiao, Jing Fu, Juan Li, Gang Hu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 51274 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |